, Volume 191, Issue 3, pp 805–811 | Cite as

Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait

  • Jose J. MateosEmail author
  • Francisco Lomeña
  • Eduard Parellada
  • Font Mireia
  • Emili Fernandez-Egea
  • Javier Pavia
  • Alberto Prats
  • Francisca Pons
  • Miquel Bernardo
Original Investigation



Drug induced parkinsonism (DIP) is directly related to dopamine D2 receptor blockade. However, there are many references describing parkinsonian signs (PS) in naive-patients. In our previous study, we observed lower DAT binding in a group of first-episode schizophrenic patients after short-term treatment with risperidone, compared with age-matched healthy controls.


To clarify if DAT decrease could be an illness trait, excluding the effect of antipsychotics on DAT availability, and to determine whether DAT availability before treatment with antipsychotics may predict subsequent development of PS.

Materials and methods

A new series of 20 neuroleptic-naive schizophrenic patients and 15 healthy subjects was recruited. SPECT with [123I] FP-CIT (DaTSCAN®) was performed before starting antipsychotics and after 4 weeks of treatment. PS and psychopathological status were assessed by the Simpson–Angus (SAS), CGI and PANSS scales. Quantitative analyses of SPECTs were performed using ROIs placed in the caudate, putamen and occipital cortex.


Schizophrenic patients showed lower DAT binding compared with the healthy subjects at baseline (p<0.001) and after a 4-week-treatment period (p=0.001). Six out of eight schizophrenic patients of the DIP group were symptomatic for PS at baseline, in comparison to two out of 12 in the NoDIP group. Nonetheless, no differences were observed on DAT between DIP and NoDIP, neither at baseline (p=0.360) nor at endpoint (p=0.984). Finally, no differences between baseline–endpoint DAT binding were observed, neither in the DIP group (p=0.767) nor in the NoDIP group (p=0.093).


Our new series of first-episode naive-schizophrenic patients (1) points out DAT dysfunction as an illness trait due to the significantly lower DAT binding in schizophrenic patients in comparison to healthy subjects; (2) supports the results of other authors who describe PS in never-treated patients; (3) confirms that [123I] FP-CIT does not allow us to predict which patients will develop parkinsonism due to the lack of differences between DIP and NoDIP patients; and (4) confirms a null effect of antipsychotics on DAT due to the lack of differences in [123I] FP-CIT before and after a 4-week-treatment period.


Neuroleptic-naive Schizophrenia Parkinsonism Dopamine transporter SPECT 



Grants from the Hospital Clínic of Barcelona (Premi Fi de Residencia 2001), Marató TV3 (Enfermedades Psiquiátricas Graves; 2001) and FIS PI02/0485 are gratefully acknowledged. Thanks to Mr. Jover L, Ph.D., and to Ms. Sugranyes G, M.D., for their statistical and English assistance, respectively.


  1. American Psychiatric Association (APA) (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Washington, USAGoogle Scholar
  2. Bernardo M, Parellada E, Lomeña F, Catafau A, Font M, Gómez J, Lopez-Carrero C, Gutierrez F, Pavia J, Salamero M (2001) Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline–endpoint [123I] IBZM SPECT study. Psychiatry Research Neuroimaging 107:87–97CrossRefGoogle Scholar
  3. Bleuler E (1911) Dementia praecox or the group of schizophrenias (trans. J. Zinkin: Dementia Praecox ode der Gruppe der Schizophrenien. In: Aschaffenburg PG (ed) Handbuch der Geiteskrankheiten. Leipzig: Deutike). International Universities Press, New York, 1950Google Scholar
  4. Booij J, Tissingh G, Winogrodzca A, Van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171–182PubMedCrossRefGoogle Scholar
  5. Booij J, Bergmans P, Winogrodzca A, Speelman JD, Wolters E (2001a) Imaging of Dopamine Transporters with [123I] FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson’s disease. Synapse 39:101–108PubMedCrossRefGoogle Scholar
  6. Booij J, Speelman J, Horstink MW, Wolters E (2001b) The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266–272PubMedCrossRefGoogle Scholar
  7. Bressan RA, Pilowsky LS (2000) Imaging the glutamatergic system in vivo—relevance to schizophrenia. Eur J Nucl Med 27:1723–1731PubMedCrossRefGoogle Scholar
  8. Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18F-DOPA PET study. Neurology 43:552–556Google Scholar
  9. Caliguri M, Lohr J, Jeste D (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 150:1343–1348Google Scholar
  10. Catafau A, Tolosa E (2004) Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 19:1175–1182PubMedCrossRefGoogle Scholar
  11. Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247–265PubMedCrossRefGoogle Scholar
  12. Corrigan PW, Liberman RP, Engel JD (1990) From noncompliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 41:1203–1211PubMedGoogle Scholar
  13. Drew AE, Werling LL (2003) Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophr Res 65:47–55PubMedCrossRefGoogle Scholar
  14. First MB, Spitzer RL, Williams JBW, Gibbon M (1994) Structured clinical interview for DSM-IV-Patients edition (SCID-P). American Psychiatric Press, Washington, DCGoogle Scholar
  15. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298:27–30PubMedCrossRefGoogle Scholar
  16. Guy W (1976) Early clinical drug evaluation unit (ECDEU), vol 76. National Institute of Mental Health, Rockville, USA, p 338Google Scholar
  17. Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32:215–228PubMedCrossRefGoogle Scholar
  18. Kay SR, Fisbein S, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:262–273Google Scholar
  19. Kraepelin E (1919) Dementia praecox and paraphrenia. University of Edinburgh, EdinburghGoogle Scholar
  20. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Räkköläinen V, Syvälahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic naïve patients with schizophrenia studied with PET. Am J Psychiatry 157:269–271PubMedCrossRefGoogle Scholar
  21. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Sivälahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115–120PubMedCrossRefGoogle Scholar
  22. Laruelle M, Abi-Dargham A, Van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R (2000) Dopamine and serotonin transporter in patients with schizophrenia: an imaging study with 123I-βCIT. Biol Psychiatry 47:371–379PubMedCrossRefGoogle Scholar
  23. Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken J, Gersons B, Van Royen E (2001) Dopamine transporter density in young patients with schizophrenia assessed with [123I] FP-CIT SPECT. Schizophr Res 47:59–67PubMedCrossRefGoogle Scholar
  24. Lewis D, Pierri J, Volk D, Melchitzky DS, Woo T (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616–626PubMedCrossRefGoogle Scholar
  25. Li S, Kim KY, Kim JH, Kin JH, Park MS, Bahk JY, Kim MO (2004) Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 363:29–32PubMedCrossRefGoogle Scholar
  26. Lieberman JA, Kinon BL, Loebel AD (1990) Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 16:97–110PubMedGoogle Scholar
  27. Mateos JJ, Lomeña F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M (2005) Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181:401–406PubMedCrossRefGoogle Scholar
  28. McCreadie RG, Thara R, Kamath D, Padmavati R, Latha S, Mathrubootham N, Menon S (1996) Abnormal movements in never medicated Indian patients with schizophrenia. Br J Psychiatry 168:221–226PubMedCrossRefGoogle Scholar
  29. McCreadie R, Padmavati R, Thara R, Srinivasan TN (2002) Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 181:135–137PubMedCrossRefGoogle Scholar
  30. Miller LG, Jankovic J (1990) Neuroleptic approach to drug-induced movement disorders: a study of 125 patients. South Med J 83:525–532PubMedGoogle Scholar
  31. Peralta V, Cuesta M, Campos MS (2002) Síntomas extrapiramidales en pacientes esquizofrénicos nunca tratados con neurolépticos. Aula Médica Psiquiátrica 4:269–280Google Scholar
  32. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 10:644–646Google Scholar
  33. Reader TA, Ase AR, Huang N, Hebert C, Van Gelder NM (1998) Neuroleptics and dopamine transporters. Neurochem Res 23:73–80PubMedCrossRefGoogle Scholar
  34. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286PubMedCrossRefGoogle Scholar
  35. Rivest R, Falardeau P, Di Paolo T (1995) Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:269–272PubMedCrossRefGoogle Scholar
  36. Schmitt GJ, Frodl T, Dresel S, La Fougere C, Bottlender R, Koutsouleris N, Hahn K, Moller Hj, Meisenzahl EM (2006) Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256:115–121PubMedCrossRefGoogle Scholar
  37. Seeman MV (1997) Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154:1641–1647Google Scholar
  38. Simpson GM, Angus JW (1970) A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 212(Suppl):11–19Google Scholar
  39. Sjoholm H, Bratlid T, Sundsfjord J (2004) 123I β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology 173:27–31PubMedCrossRefGoogle Scholar
  40. Tatsch K (2001) Imaging of the dopaminergic system in parkinsonism with SPECT. Nucl Med Commun 22:819–827PubMedCrossRefGoogle Scholar
  41. Tatsch K, Scherer J, Linke R, Kerner M, Hahn K (1999) Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.). J Nucl Med 40:31Google Scholar
  42. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, Van Royen EA (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-ebeta-(4-iodophenyl)-tropane SPECT in healthy controls and early-stage, drug-naïve Parkinson’s disease. J Nucl Med 39:1143–1148PubMedGoogle Scholar
  43. Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18:S28–S33PubMedCrossRefGoogle Scholar
  44. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T (2000) Cholinergic neuronal modulation alters dopamine d2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci 20:7067–7073PubMedGoogle Scholar
  45. Valchar M, Hanbauer I (1993) Comparison of 3HWIN 35,428 binding, a marker for dopamine transporter, in embrionyc mesencephalic neuronal cultures with striatal membranes of adult rats. J Neurochem 60:469–476PubMedCrossRefGoogle Scholar
  46. Van Dyck Ch, Seibyl J, Malison R, Laruelle M, Zoghhi S, Baldwin R, Innis R (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects and hemispheric asymmetries. Am J Geriatr Psychiatry 10:36–46PubMedCrossRefGoogle Scholar
  47. Verhoeff NPLG (1999) Radiotracers imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 147:217–249PubMedCrossRefGoogle Scholar
  48. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CLE (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134–140PubMedCrossRefGoogle Scholar
  49. Wolff A, O’Driscoll G (1999) Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at risk. J Psychiatry Neurosci 24:304–314PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Jose J. Mateos
    • 1
    Email author
  • Francisco Lomeña
    • 1
  • Eduard Parellada
    • 2
  • Font Mireia
    • 2
  • Emili Fernandez-Egea
    • 2
  • Javier Pavia
    • 1
  • Alberto Prats
    • 3
  • Francisca Pons
    • 1
  • Miquel Bernardo
    • 2
  1. 1.Nuclear Medicine Department, Hospital Clínic of BarcelonaUniversity of BarcelonaBarcelonaSpain
  2. 2.Psychiatry Department, Hospital Clínic of BarcelonaUniversity of BarcelonaBarcelonaSpain
  3. 3.Anatomy DepartmentUniversity of BarcelonaBarcelonaSpain

Personalised recommendations